Dr. Rany Aburashed

Chief Executive Officer/Founder Neurogen Biomarking

[Dr. Rany Aburashed @RanyAburashed]

https://t.co/UpgDicbEjg

[Dr. Rany Aburashed @RanyAburashed]

How Neurogen Biomarking Is Ushering In A New Era Of Brain Health https://t.co/c6O1vX8WqR

[Dr. Rany Aburashed @RanyAburashed]

Neurogen Biomarking: The Company That’s Changing the Future of Brain Health https://t.co/RVAtyyIGOb via @usatoday

[Dr. Rany Aburashed @RanyAburashed]

@DrOz Outstanding! Congratulations to Oliver and to both you and Lisa. More importantly he’s as kind as he is intelligent.

[Dr. Rany Aburashed @RanyAburashed]

Neurogen Biomarking Announces Global Agreement with Quanterix for Use of Blood Biomarker Assay in its Patient-Initiated Blood Test to Support Early Detection of Dementia and Mild Cognitive Impairment Due to Alzheimer’s Disease https://t.co/EbS9SmxHFm

[Dr. Rany Aburashed @RanyAburashed]

@AdnanSubei @AANMember Well deserved! One of the best men I know. Great clinician and great heart.

[MultipleSclerosis_CME @ms_cme]

Join here tomorrow for the launch of a new accredited #tweetorial on "Insights into #MultipleSclerosis disease course through the Topographical Model of #MS"! Earn 0.5 CE/CME credits: #physicians, #nurses, #pharmacists! Expert faculty is @SKriegerMD.

[MultipleSclerosis_CME @ms_cme]

36) That's it! You made it! Free CE/#CME! Now go to https://t.co/epzCXGoRpL and claim your credit! I am @RanyAburashed. Follow @MS_CME for more tweetorials, and visit us at https://t.co/rUou3c5Z2j and . . .

[MultipleSclerosis_CME @ms_cme]

35) suboptimal treatment response, and hopefully serve as predictive models where early intervention can change the natural history of disease on an individual level.

[MultipleSclerosis_CME @ms_cme]

34) Summary: MS prognosis remains difficult to predict on an individual basis! Emerging individual serum biomarkers or a collection of bioprofiles may help in earlier detection of disease progression,

[MultipleSclerosis_CME @ms_cme]

33) CHIL31 levels at baseline also have been found to correlate with disability progression in patients with MS. Multiple Sclerosis 2015;21(14): 1761-1770. Brain 2010;133:1092-1093

[MultipleSclerosis_CME @ms_cme]

32) Chitinase 3-Like 1 or CHI3L1 is a glycoprotein expressed in activated glia, activated macrophages, and vascular smooth muscle. It is overexpressed in patients with CIS who convert to cdMS and is also correlated with GAD enhancing lesions on MRI.

[MultipleSclerosis_CME @ms_cme]

31) Elevated GFAP levels have been shown to be associated with disability severity and ambulatory loss in patients with MS. Brain 2002; 125(Pt. 7): 1462–1473.

[MultipleSclerosis_CME @ms_cme]

30) GFAP is another important potential marker for disease monitoring/prognostication. It is an astrocytic cytoskeletal protein that is highly expressed in astrogliosis in MS lesions.

[MultipleSclerosis_CME @ms_cme]

29) The answer is (a), clinical relapse or disease activity.

[MultipleSclerosis_CME @ms_cme]

28) Elevated neurofilament light levels most likely represent which of the following?
a. Clinical relapse or disease activity
b. MS subtype
c. Cognitive decline
d. DMT optimal response

[MultipleSclerosis_CME @ms_cme]

27) . . . making this a promising prospect to monitor disease activity as well as treatment response during routine clinical care. J Neurol Neurosurg Psych 2016;87:126. Serum NfL levels are particularly high in pwMS with gadolinium enhancing MRI lesions. Ann Neurol 2017;81:857

[MultipleSclerosis_CME @ms_cme]

26) Recent advances in ELISA assays using Single Molecule Array Assays (SIMOA) have led to the potential utility of measuring Neurofilaments in biofluid with high correlation to CSF . . .